1. MYCN

    Comments Leave a Comment

    1-15 of 193 1 2 3 4 ... 11 12 13 »
    1. Mentioned In 193 Articles

    2. New research points to potential targeted treatments of neuroblastoma tumours

      New research points to potential targeted treatments of neuroblastoma tumours
      ...th tumour genotype is a relatively new idea," said Applebaum. "We tried to link germline characteristics with MYCN-amplified versus non-MYCN-amplified tumours." Further studies are needed to build on the research and eve...
      Read Full Article
      Mentions: MYCN
    3. Potential for more targeted treatments of neuroblastoma tumors

      ...ith tumor genotype is a relatively new idea," said Applebaum. "We tried to link germline characteristics with MYCN-amplified versus non-MYCN-amplified tumors." Further studies are needed to build on the research and even...
      Read Full Article
      Mentions: MYCN
    4. New research points to potential for more targeted treatments of neuroblastoma tumors

      New research points to potential for more targeted treatments of neuroblastoma tumors
      ...ith tumor genotype is a relatively new idea," said Applebaum. "We tried to link germline characteristics with MYCN-amplified versus non-MYCN-amplified tumors." Further studies are needed to build on the research and even...
      Read Full Article
      Mentions: MYCN
    5. The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis.

      ...alignancy that includes a high-risk subset for which new therapeutic agents are urgently required. As well as MYCN amplification, activating point mutations of ALK and NRAS are associated with high-risk and relapsing neu...
      Read Full Article
      Mentions: ALK MYCN
    6. Accelerating Drug Development for Neuroblastoma - New Drug Development Strategy: An Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neu

      ...e-clinical data; potential combinations; biomarkers), identifying as priority targets ALK, MEK, CDK4/6, MDM2, MYCN (druggable by BET bromodomain, aurora kinase, mTORC1/2) BIRC5 and checkpoint kinase 1; 3) promoted clinic...
      Read Full Article
      Mentions: ALK MYCN
    7. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.

      ...us or dinutuximab, stratified by disease category, previous exposure to anti-GD2 antibody therapy, and tumour MYCN amplification status. Patients in both groups received oral temozolomide (100 mg/m2 per dose) and intrave...
      Read Full Article
      Mentions: COG Refractory MYCN
    8. Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

      ...eatures: Patients with INRG stage MS disease with MYCN amplification Patients with INRG stage L2 disease with MYCN amplification Patients > 547 days of age initially diagnosed with INRG stage L1, L2 or MS disease who pro...
      Read Full Article
      Mentions: Treatment INRG ALK
    9. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

      ...c studies showed μM concentrations consistent with cytotoxic levels in preclinical models. Nine patients (all MYCN-non-amplified) remained progression-free through 43+ to 74+ (median 54+) months from study entry, includi...
      Read Full Article
      Mentions: MYCN
    10. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.

      ...ctors and overall survival (OS) were statistically evaluated. In SH-SY5Y, an MYCN-non-amplified, and LAN5, an MYCN-amplified NB cell lines, miR-149 was either upregulated or downregulated by lentiviral transduction, to e...
      Read Full Article
      Mentions: MYCN
    11. 1-15 of 193 1 2 3 4 ... 11 12 13 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes about MYCN

    1. We showed that maintenance of high MYCN protein levels is a key issue for this MYCN driven cancer. Neuroblastoma cells often have over 100 copies of the MYCN gene - so they produce an enormous amount of MYCN protein.
      In A way to target the Achilles heel of neuroblastoma
    2. Children with a MYCN-amplification event, which occurs in about 25 percent of cases, have the poorest prognosis.
      In Loss of a microRNA family, let-7, found key in neuroblastoma
    3. Once a tumor has disrupted let-7 genetically, it doesn't need to amplify MYCN because it doesn't need to sponge let-7.
      In Loss of a microRNA family, let-7, found key in neuroblastoma